Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of
cancer. Genetic and biochemical data have demonstrated that the growth and motility factor …

c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth
factor, activates a wide range of different cellular signaling pathways, including those …

Carcinoma of the stomach is still the second most common cause of cancer death
worldwide, although the incidence and mortality have fallen dramatically over the last 50 …

The MET tyrosine kinase stimulates cell scattering, invasion, protection from apoptosis and
angiogenesis, thereby acting as a powerful expedient for cancer dissemination. MET can …

Purpose Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may
constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow …

The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have
been implicated in the progression of several human cancers and are attractive therapeutic …

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate
multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This …

Oncogenic gene fusions have been identified in many cancers and many serve as
biomarkers or targets for therapy. Here we identify six different melanocytic tumours with …

Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib,
bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class …

BACKGROUND The c‐met and the c‐erb B‐2 protooncogenes belong to a family of tyrosine
kinase growth factor receptors. Abnormalities of these oncogenes and protein products have …